<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00012090</url>
  </required_header>
  <id_info>
    <org_study_id>00-054</org_study_id>
    <secondary_id>CDR0000068483</secondary_id>
    <secondary_id>NCI-G01-1918</secondary_id>
    <nct_id>NCT00012090</nct_id>
  </id_info>
  <brief_title>Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum</brief_title>
  <official_title>A Phase II Trial Of Oral Bicalutamide With Subcutaneous Goserelin In Patients With Epithelial Ovarian, Fallopian Tube, Or Peritoneal Carcinoma In Second Or Greater Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep&#xD;
      growing. Goserelin may interfere with the growth factor and may stop the tumor from growing.&#xD;
      Bicalutamide may prevent androgens from stimulating the growth of cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of goserelin plus bicalutamide in treating&#xD;
      patients who have refractory or recurrent cancer of the ovary, fallopian tube, or peritoneum.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the time-to-treatment failure in patients with ovarian epithelial,&#xD;
      fallopian tube, or peritoneal carcinoma, in second or greater remission, treated with&#xD;
      bicalutamide and goserelin. II. Assess luteinizing hormone and follicle-stimulating hormone&#xD;
      suppression in correlation with serum vascular endothelial growth factor levels, and&#xD;
      determine if these levels are related to time to treatment failure in these patients. III.&#xD;
      Correlate the presence or absence of androgen receptor tissue expression by&#xD;
      immunohistochemistry and androgen receptor gene trinucleotide repeat length to time to&#xD;
      treatment failure in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive oral bicalutamide once daily and goserelin subcutaneously once&#xD;
      every 4 weeks. Treatment continues in the absence of unacceptable toxicity until disease&#xD;
      recurrence.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <completion_date type="Actual">April 2004</completion_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bicalutamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>goserelin acetate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed epithelial carcinoma arising in the&#xD;
        ovary, fallopian tube, or peritoneum, in second or greater remission Failed initial therapy&#xD;
        with persistent or recurrent disease Cytoreductive surgery AND At least 1 platinum-based&#xD;
        chemotherapy regimen No evidence of disease within 4 months of salvage chemotherapy CA-125&#xD;
        less than 35 U Negative physical exam No abdominal or pelvic disease by CT&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Adult Performance status: Karnofsky 60-100% Life expectancy:&#xD;
        Not specified Hematopoietic: Absolute neutrophil count at least 1,000/mm3 Platelet count at&#xD;
        least 100,000/mm3 Hepatic: Bilirubin less than 2 times upper limit of normal (ULN) SGOT&#xD;
        less than 2 times ULN Alkaline phosphatase less than 2 times ULN Renal: Not specified&#xD;
        Other: No other active invasive malignancy No inability to receive subcutaneous injection&#xD;
        No inability to tolerate oral medication&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease&#xD;
        Characteristics Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: See&#xD;
        Disease Characteristics Other: No concurrent oral anticoagulants&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Sabbatini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, Lewin S, Konner J, Derosa F, Spriggs D, Iasonos A, Sabbatini P. A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. Cancer. 2007 Dec 1;110(11):2448-56.</citation>
    <PMID>17918264</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>March 3, 2001</study_first_submitted>
  <study_first_submitted_qc>November 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2003</study_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2013</last_update_posted>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

